About Dyne Therapeutics, Inc. - Common Stock (DYN)
Dyne Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with serious muscle diseases, particularly those caused by genetic mutations. The company leverages its proprietary Dynamic™ approach to design and deliver targeted medicines that can modulate gene expression and address the underlying causes of these conditions. By utilizing advanced technologies, Dyne aims to provide transformative treatment options that enhance the quality of life for individuals affected by muscle disorders, while also advancing its pipeline of therapeutic candidates through various stages of development. Read More
The DJS Law Group announces that it is investigating claims on behalf of investors of Dyne Therapeutics (“Dyne” or “the Company”) (NASDAQ: DYN) for violations of the securities laws.
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval -
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne’s Compensation Committee and made as an inducement material to the new employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera’s acceptance of employment with Dyne under Dyne’s 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET.
